TheraRadar
← Back
Data updated: Mar 29, 2026

AKEBIA

MetabolicCardiovascularGastroenterology
Pharma

AKEBIA is a pharmaceutical company focused on Metabolic, Cardiovascular, Gastroenterology. Key products include VAFSEO.

2024
Since
1
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

VAFSEO
vadadustat
HIF-prolyl-4-hydroxylases 2 indications · 2024

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 40%
0 drugs Phase 2: 1
Cardiovascular 40%
0 drugs Phase 2: 1
Gastroenterology 20%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Cardiovascular, Metabolic
QUAGEN specialty
Metabolic, Gastroenterology, Cardiovascular
Johnson & Johnson big-pharma
Cardiovascular, Metabolic
Bayer big-pharma
Cardiovascular, Metabolic
B BRAUN specialty
Metabolic, Cardiovascular